Learn More
OBJECTIVE We investigated changes in serum uric acid across pregnancy in women with gestational hyperuricemia at delivery, with and without preeclampsia, compared with normal pregnant and women with preeclampsia without gestational hyperuricemia. STUDY DESIGN This was a nested case-control study of 116 controls, 27 women with preeclampsia with predelivery(More)
OBJECTIVE We measured maternal serum soluble fms-like tyrosine kinase 1 concentrations across pregnancy and immediately postpartum in women who developed preeclampsia and normal pregnant women. STUDY DESIGN This was a nested case control study of 113 normal pregnant women and 55 women with preeclampsia. RESULTS Serum soluble fms-like tyrosine kinase 1(More)
The acute safety of the alternative chlorofluorocarbon-free (CFC-free) propellant HFA-134a from a pressurized metered-dose inhaler (MDI) was assessed in 12 healthy male subjects according to a double-blind, randomized, crossover design. On each of three consecutive days, cumulative doses of 1,2,4,8 and 16 inhalations were administered 30 min apart from one(More)
A 28-day double-blind parallel group study has been conducted to compare the safety and tolerability of HFA-134a, a chlorofluorocarbon-free propellant in a pressurized metered-dose inhaler (MDI A), with a chlorofluorocarbon propellant (MDI C). Sixteen subjects were randomly assigned to receive one of the two MDIs, either four inhalations four times per day(More)
Sera from patients with chronic lung diseases were tested for the presence of immune complexes (ICs) by the 125I-C1q-binding assay. Contrary to earlier reports, modification of the test system by addition of heparin decreased rather than increased the ability of the test to discriminate between control and pathological sera. Using the unmodified system,(More)
The objective of this study was to determine if salbutamol was absorbed from a new salbutamol sulfate chlorofluorocarbon (CFC)-free metered-dose inhaler (MDI). Measurement of HFA-134a, the CFC-free propellant, was included to provide proof of delivery of this MDI. Eight healthy men received two inhalations (90 micrograms salbutamol base equivalents per(More)
Circulating immune complex (IC) levels in sera from 58 healthy controls and a total of 212 patients with various chronic lung diseases were measured using 3 assays. Two complement-dependent assays (C1q fluid phase and Raji) and a complement-independent assay (L1210) were employed. The 3 assays generally revealed similar patterns of reactivity when control(More)
A major difference in molecular size of material reactive in the C1q binding assay and two cellular assays (Raji and L1210) for immune complexes, is reported. Elevated C1q binding of pathological sera was associated with material in the range 7-19S, as determined by Sepharose 6B chromatography of sera from patients with chronic inflammatory and neoplastic(More)
Treatment of artificial immune complexes (ICs) with 2.5% polyethylene glycol (PEG)--conditions under which C1q-binding activity is routinely measured in the fluid phase--produced marked changes in molecular size as determined by Sepharose 6B chromatography. The effect of PEG on the C1q-binding capacity of ICs, was therefore investigated using a solid phase(More)
Four patients with severe bronchiectasis (chronic bronchial suppuration) are described who developed cutaneous lesions associated with exacerbations of their respiratory disease. The skin abnormalities consisted of purpuric lesions in three patients and an erythematous vasculitis in one. Circulating immune complexes were present in all patients and in three(More)